Patents by Inventor Christian Che

Christian Che has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180221497
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 9, 2018
    Inventors: Richard BÉLIVEAU, Michel DEMEULE, Christian CHE, Anthony REGINA
  • Patent number: 9914754
    Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 13, 2018
    Assignee: Angiochem Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Catherine Gagnon
  • Publication number: 20180015180
    Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
    Type: Application
    Filed: February 22, 2017
    Publication date: January 18, 2018
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot-sabot, Laurence Peslherbe
  • Publication number: 20170326233
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an anti-body moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 16, 2017
    Inventors: Michel Demeule, Christian Che, Sanjoy Das, Gaoqiang Yang
  • Publication number: 20170281787
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: November 11, 2016
    Publication date: October 5, 2017
    Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
  • Patent number: 9713646
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: July 25, 2017
    Assignee: Angiochem Inc.
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20170080100
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting an antibody or antibody fragment across the blood-brain barrier of an individual and in the treatment and diagnosis of neurological diseases.
    Type: Application
    Filed: January 21, 2016
    Publication date: March 23, 2017
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20160375145
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Inventors: Michel DEMEULE, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
  • Publication number: 20160263236
    Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
    Type: Application
    Filed: October 23, 2015
    Publication date: September 15, 2016
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot-Sabot, Laurence Peslherbe
  • Publication number: 20160263235
    Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic. The compounds of the invention can be used to treat any disease for which the peptide therapeutic is useful.
    Type: Application
    Filed: April 24, 2015
    Publication date: September 15, 2016
    Inventors: JEAN-PAUL CASTAIGNE, MICHEL DEMEULE, CHRISTIAN CHE, CARINE THIOT, CATHERINE GAGNON, BETTY LAWRENCE
  • Patent number: 9365634
    Abstract: Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: June 14, 2016
    Assignee: Angiochem Inc.
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20160106856
    Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.
    Type: Application
    Filed: August 14, 2013
    Publication date: April 21, 2016
    Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
  • Publication number: 20150314010
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Application
    Filed: March 2, 2015
    Publication date: November 5, 2015
    Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 9161988
    Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 20, 2015
    Assignee: Angiochem Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Catherine Gagnon, Betty Lawrence
  • Publication number: 20150174267
    Abstract: The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.
    Type: Application
    Filed: March 6, 2015
    Publication date: June 25, 2015
    Inventors: Jean-Paul CASTAIGNE, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20150174266
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.
    Type: Application
    Filed: August 12, 2014
    Publication date: June 25, 2015
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 8969310
    Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: March 3, 2015
    Assignee: Angiochem Inc.
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Publication number: 20150038429
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.
    Type: Application
    Filed: July 11, 2014
    Publication date: February 5, 2015
    Inventors: Michel DEMEULE, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
  • Patent number: 8828925
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: September 9, 2014
    Assignee: Angiochem Inc.
    Inventors: Michel Demeule, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
  • Patent number: 8828949
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: September 9, 2014
    Assignee: Angiochem, Inc.
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina